References
Benedix F, Reimer A, Gastinger I, Mroczkowski P, Lippert H, Kube R. Primary appendiceal carcinoma--epidemiology, surgery and survival: results of a German multi-center study. Eur J Surg Oncol. 2010;36(8):763-71. doi:https://doi.org/10.1016/j.ejso.2010.05.025.
The Chicago Consensus on peritoneal surface malignancies: Management of appendiceal neoplasms. Cancer. 2020;126(11):2525-33. doi:https://doi.org/10.1002/cncr.32881.
Milovanov V, Sardi A, Ledakis P, Aydin N, Nieroda C, Sittig M et al. Systemic chemotherapy (SC) before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with peritoneal mucinous carcinomatosis of appendiceal origin (PMCA). Eur J Surg Oncol. 2015;41(5):707-12. doi:https://doi.org/10.1016/j.ejso.2015.01.005.
Kolla BC, Petersen A, Chengappa M, Gummadi T, Ganesan C, Gaertner WB et al. Impact of adjuvant chemotherapy on outcomes in appendiceal cancer. Cancer Med. 2020;9(10):3400-6. doi:https://doi.org/10.1002/cam4.3009.
Blackham AU, Swett K, Eng C, Sirintrapun J, Bergman S, Geisinger KR et al. Perioperative systemic chemotherapy for appendiceal mucinous carcinoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Surg Oncol. 2014;109(7):740-5. doi:https://doi.org/10.1002/jso.23547.
Lieu CH, Lambert LA, Wolff RA, Eng C, Zhang N, Wen S et al. Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix. Ann Oncol. 2012;23(3):652-8. doi:https://doi.org/10.1093/annonc/mdr279.
Sugarbaker PH, Bijelic L, Chang D, Yoo D. Neoadjuvant FOLFOX chemotherapy in 34 consecutive patients with mucinous peritoneal carcinomatosis of appendiceal origin. J Surg Oncol. 2010;102(6):576-81. doi:https://doi.org/10.1002/jso.21679.
Author information
Authors and Affiliations
Contributions
• RB Morgan: protocol/project development, data collection or management, data analysis, manuscript writing/editing.
• A Yan: protocol/project development, data collection or management, data analysis.
• A Dhiman: protocol/project development, data analysis, manuscript editing.
• A Shergill: protocol/project development, manuscript editing.
• B Polite: protocol/project development, manuscript editing.
• KK Turaga: protocol/project development, manuscript writing/editing.
• OS Eng: protocol/project development, data analysis, manuscript writing/editing.
Corresponding author
Ethics declarations
Ethics Approval
Retrospective review and collection of patient data was approved by the University of Chicago institutional review board (protocol # 19–0793). No further approval was required for this retrospective study.
Conflict of Interest
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Poster Presentation: American Society of Clinical Oncology Gastrointestinal Cancers Symposium. San Francisco, CA. January 22, 2022. Poster Presentation: International Conference on Surgical Cancer Care and Advanced Cancer Therapies. Dallas, TX. March 11, 2022.
Rights and permissions
About this article
Cite this article
Morgan, R.B., Yan, A., Dhiman, A. et al. Survival in Total Preoperative vs. Perioperative Chemotherapy for Patients with Metastatic High-Grade Appendiceal Adenocarcinoma Undergoing CRS/HIPEC. J Gastrointest Surg 26, 2591–2594 (2022). https://doi.org/10.1007/s11605-022-05423-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11605-022-05423-9